
Noa Dagan
Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control
An Observational Emulation of a Target Trial
Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are both recommended as second-line treatments for individuals with Type 2 diabetes and obesity, but long-term head-to-head randomized trials in this population are lacking, necessitating a real-world evaluation of their relative benefits in weight loss and glycaemic control. Materials and Methods: Using observational data from Clalit's medical records, separate target trials were emulated comparing three GLP-1 RAs (liraglutide, dulaglutide and semaglutide) with SGLT-2is in individuals with Type 2 diabetes and obesity. The main outcomes were absolute changes in body weight and HbA1c during follow-up (up to 5 years for liraglutide/dulaglutide and 3 years for semaglutide). We used inverse-probability weighting to adjust for potential confounders. Results: We identified 4296, 11 159 and 5041 eligible individuals initiating liraglutide, dulaglutide and semaglutide, respectively. Long-term weight loss was similar (6.4–7.3 kg at 5 years) for liraglutide and dulaglutide compared with SGLT-2is; weight loss for semaglutide was 2.6 kg (95% CI: 1.2–4.0) greater than for SGLT-2is at 18 months. At 18 months, HbA1c reductions were 0.4% (95% CI: 0.3–0.5), 0.7% (95% CI: 0.6–0.8) and 0.6% (95% CI: 0.5–0.8) greater for liraglutide, dulaglutide and semaglutide than SGLT-2is, respectively; this advantage was maintained throughout follow-up. Conclusions: We estimated that, compared with SGLT-2is, liraglutide and dulaglutide provided superior glycaemic control and similar weight reduction over 5 years, and that semaglutide produced greater short-term reductions in both outcomes. Our analyses benchmark the results of short-term randomized trials and extend the evidence to longer periods.
| Publication language | English |
| Journal | Diabetes, Obesity and Metabolism |